Drug intelligence / Profile preview

TJAOA103

Development stage: Phase 1
Lead developer: Tongji Hospital
Administration: Oral

Overview

**TJAOA103** is a proprietary traditional Chinese medicine herbal formula developed by Tongji Hospital for genitourinary syndrome of menopause. It is being evaluated in a prospective, single-arm Early Phase 1 clinical study in which participants receive the formula twice daily for 4 to 12 weeks. The publicly available trial record does not disclose the individual herbal constituents, standardized active ingredients, direct molecular targets, or a defined target-level mechanism of action. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07160127))

Other names: Tongji Anti-Ovarian Aging 103

Beyond the preview

Go deeper on TJAOA103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJAOA103.

Explore the full profile